Key clinical point: Galcanezumab reduces the frequency of migraine headache days and may also potentially decrease disabling non-pain symptoms on days when migraine is present in patients with episodic and chronic migraine.
Major finding: Galcanezumab doses of 120 and 240 mg were superior to placebo in reducing the number of monthly migraine days with nausea and/or vomiting in both episodic and chronic migraine studies (all P less than .001). Both doses of galcanezumab were associated with a significant reduction in migraine headache days with photophobia and phonophobia vs. placebo in episodic ( P less than .001 ) and chronic ( P less than .001 for galcanezumab 120 mg; P =.001 for galcanezumab 240 mg ) migraine studies.
Study details: A post hoc analysis of phase 3 randomized clinical trials EVOLVE-1, EVOLVE-2, and REGAIN that included a total of 2,289 patients with episodic or chronic migraine with or without aura.
Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. K Day, VL Stauffer , V Skljarevski, M Rettiganti, E Pearlman, and SK Aurora reported being current/former full-time employees and/or minor stockholders of Eli Lilly and Company. M Ament reported being a consultant and/or on speaker bureaus for Eli Lilly and Company and others .
Source: Ament M et al. J Headache Pain. 2021 Feb 6. doi: 10.1186/s10194-021-01215-9.